Edgar Filing: Wolff Henry Ward - Form 4

Form 4	•										
December 1									OMB AF	PROVAL	
FORM	/1 4 UNITED	STATES			AND EX 1, D.C. 2(NGE CC	MMISSION	OMB Number:	3235-0287	
Check the										January 31,	
if no lon subject t Section Form 4	to SIAIE N 16.									Expires: 2005 Estimated average burden hours per response 0.5	
Form 5 obligatio may cor <i>See</i> Instr 1(b).	ons Section 17(a) of the P	ublic U	tility Ho	lding Coi	npan	•	Act of 1934, 935 or Section			
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> Wolff Henry Ward			2. Issuer Name and Ticker or Trading Symbol PORTOLA PHARMACEUTICALS					5. Relationship of Reporting Person(s) to Issuer			
			INC [P		AKMACI	2011	(Check all applicable)				
(Last) C/O PORT PHARMAG EAST GRA		3. Date of Earliest Transaction(Month/Day/Year)12/15/2017					_X_ Director10% Owner Officer (give titleOther (specify below) below)				
SOUTH SA	4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	CO, CA 94080 (State)	(Zip)				_					
(City)				le I - Non-			-	red, Disposed of,	or Beneficiall	y Owned	
1.Title of Security 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date any (Month/Day/Year) (Instr. 3) any (Month/Day/		Date, if Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) y/Year) (Instr. 8) (A) or				(D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	rities Ownership eficially Form: ned Direct (D) owing or Indirect orted (I) usaction(s) (Instr. 4)			
Common Stock	10/05/2017			М	12,000		\$ 5.3	12,000 <u>(1)</u>	I	By Henry & Marian Wolff 1999 Revoc. Trust	
Common Stock	12/15/2017			S	11,300	D	\$ 46.948 (2)	700 <u>(1)</u>	I	By Henry & Marian Wolff 1999	

Edgar Filing: Wolff Henry Ward - Form 4												
Common 12/15/2017 Stock			S	700	\$ D 47.7686		0 (1)	I	Revoc. Trust By Henry & Marian Wolff 1999 Revoc.			
									Trust			
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)												
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)												
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Conversion(Month/Day/Year)Execution Date, if anyor ExerciseanyPrice of(Month/Day/Year)Derivative			orDeriv Secu Acqu or Di (D)	rities hired (A) sposed of :. 3, 4,	6. Date Exercis Expiration Dat (Month/Day/Y	e	7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
Stock Option (Right to Buy)	\$ 5.3	10/05/2017 <u>(4)</u>		М		12,000 (1)	11/15/2007	11/14/2017	Common Stock	12,000		
Reporting Owners												
Reporting Owner Name / Address Relationships Director 10% Owner Officer Other												
270 EAST	ΤΟLA PHA Γ GRAND A	ARMACEUTICA) AVE. CISCO, CA 9408	Х									
Signa	tures											
/s/Mike Ouimette, as attorney-in-fact 12/			12/18/2017									
-	ture of Reportin	g Person	Date									

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 11, 2017.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$46.44 to \$47.38, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola

(2) Bo \$17.50, inclusive: The reporting person undertakes to provide 1 orton 1 numaceuteurs, inc., any security noted of 1 orton 1
 Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$47.55 to \$47.93, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola

(3) Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

(4) Mr. Wolff exercised these shares through a cash exercise and transferred the shares following the exercise into the Henry & Marian Wolff 1999 Revocable Trust for which Mr. Wolff is a trustee.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.